NASDAQ:RNA Avidity Biosciences Q4 2025 Earnings Results & Report $6.43 -1.08 (-14.38%) As of 04:00 PM Eastern Avidity Biosciences missed analyst expectations on both earnings and revenue in its Q4 2025 results, released February 23, 2026. The company reported EPS of -$1.59 versus the -$1.24 consensus estimate, while revenue of $860 thousand fell short of the $1.98 million estimate by $1.12 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 23, 2026TimeBefore Market OpensConference Call7:00 AM ET Avidity Biosciences EPS ResultsActual EPS-$1.59Consensus EPS -$1.24Beat/MissMissed by -$0.35One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersAvidity Biosciences Revenue ResultsActual Revenue$860 thousandExpected Revenue$1.98 millionBeat/MissMissed by -$1.12 millionYoY Revenue GrowthN/AConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Avidity Biosciences Q4 2025 Earnings FAQ Did Avidity Biosciences beat earnings estimates for Q4 2025? Avidity Biosciences (NASDAQ:RNA) reported earnings of -$1.59 per share for Q4 2025, missing the consensus estimate of -$1.24. The report was announced on Monday, February 23, 2026. What was Avidity Biosciences' revenue for Q4 2025? Avidity Biosciences reported revenue of $860 thousand for Q4 2025, against a consensus estimate of $1.98 million. Avidity Biosciences Earnings HeadlinesAvidity Biosciences, Inc. (NASDAQ:RNA) Stock Has Average Price Target of $40.80November 13 at 3:47 AM | americanbankingnews.comAtrium Therapeutics Reports Third Quarter 2026 Financial ResultsNovember 12, 2026 | prnewswire.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 16 at 1:00 AM | Base Camp Trading (Ad)Avidity Biosciences (RNA) Expected to Post Earnings on ThursdayNovember 11, 2026 | americanbankingnews.comAtrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026November 2, 2026 | prnewswire.comAtrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 SyndromeOctober 27, 2026 | prnewswire.comSee More Avidity Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avidity Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your email. Email Address About Avidity BiosciencesAvidity Biosciences (NASDAQ:RNA) is a biotechnology company focused on developing RNA-based medicines for diseases that affect muscle. Its Antibody Oligonucleotide Conjugate (AOC) platform combines antibodies with oligonucleotides to help deliver RNA-targeting treatments into muscle cells. The company’s research and clinical pipeline has included programs for neuromuscular disorders such as myotonic dystrophy type 1 and Duchenne muscular dystrophy. Avidity was founded in 2012 and is based in San Diego, California.View Avidity Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.